| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/06/2005 | WO2004078776A3 Ny-eso-1 peptides which bind to class ii molecules and uses thereof |
| 05/06/2005 | WO2004059318A3 Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation |
| 05/06/2005 | WO2004058815B1 Centrosome-associated protein and applications thereof |
| 05/06/2005 | WO2004047727A3 Compositions and methods for diagnosing and treating mood disorders |
| 05/06/2005 | WO2004044220A3 Flaviviris fusion inhibitors |
| 05/06/2005 | WO2004018619A3 P53 binding t cell receptor molecules and uses thereof |
| 05/06/2005 | WO2004015096A8 Leech extracts for stents |
| 05/06/2005 | WO2003068146A3 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 05/06/2005 | WO2003062394A3 Methods and compositions for rna interference |
| 05/06/2005 | WO2003057840A3 Compositions for dna mediated gene silencing |
| 05/06/2005 | WO2003018606A3 Casein derived peptides and uses thereof in therapy |
| 05/06/2005 | WO2002095007A3 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 05/06/2005 | WO2002072787A3 Telomerase expression repressor proteins and methods of using the same |
| 05/06/2005 | CA2747029A1 Spinning impingement multiphase contacting device |
| 05/06/2005 | CA2544099A1 Peptides with anti-obesity activity and other related uses |
| 05/06/2005 | CA2543817A1 Fibroblast-mobilization agent containing a g-csf for repair of myocardial infarct lesion |
| 05/06/2005 | CA2543630A1 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof |
| 05/06/2005 | CA2543565A1 Use of caspase-8 inhibitors for modulating hematopoiesis |
| 05/06/2005 | CA2543498A1 Use of hydroxylated amino acids for treating diabetes |
| 05/06/2005 | CA2543319A1 Methods of treating leukemia with suberoylanilide hydroxamic acid |
| 05/06/2005 | CA2543189A1 In vivo gene therapy of parkinson's disease |
| 05/06/2005 | CA2543095A1 Virally-safe factor viii with a low content of higher multimers |
| 05/06/2005 | CA2542942A1 Nucleic acids useful for triggering tumor cell lethality |
| 05/06/2005 | CA2542913A1 Oligopeptides as coating material for medical products |
| 05/06/2005 | CA2542708A1 Dna delivery with gemini cationic surfactants |
| 05/06/2005 | CA2542652A1 Nutritional composition against side effects of chemotherapy or radiotherapy |
| 05/06/2005 | CA2542172A1 Therapeutic applications for c-peptide |
| 05/06/2005 | CA2542017A1 Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
| 05/06/2005 | CA2541840A1 P185neu-encoding dna and therapeutical uses thereof |
| 05/06/2005 | CA2541123A1 Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia |
| 05/06/2005 | CA2539845A1 Methods and compositions for treating erectile dysfunction |
| 05/06/2005 | CA2534996A1 The use of sirna silencing in the prevention of metastasis |
| 05/06/2005 | CA2534828A1 Novel cxcl8 antagonists |
| 05/06/2005 | CA2532094A1 Sp1 and sp3 targeted cancer therapies and therapeutics |
| 05/06/2005 | CA2528805A1 Gsk-3 inhibitors and uses thereof |
| 05/05/2005 | US20050096632 Intradermal delivery of substances |
| 05/05/2005 | US20050096631 Intradermal delivery of substances |
| 05/05/2005 | US20050096630 Intradermal delivery of substances |
| 05/05/2005 | US20050096460 Beta-amyloid peptide-binding proteins and polynucleotides encoding the same |
| 05/05/2005 | US20050096364 Iminothiazolidinones as inhibitors of HCV replication |
| 05/05/2005 | US20050096339 for alleviating immune-cell mediated tissue destruction associated with the inflammatory response |
| 05/05/2005 | US20050096335 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 05/05/2005 | US20050096304 Method of treating cancer using dithiocarbamate derivatives |
| 05/05/2005 | US20050096292 Antisense oligonucleotides for apotopsis and chimera and expression of Notch 1 |
| 05/05/2005 | US20050096288 Antigen specific immune response by providing low density lipoprotein and a nucleic acid to be expressed as antigen bonded to each other for genes in vaccines |
| 05/05/2005 | US20050096286 Plasmid encoding of fibroblast growth factor as treatment for hypercholesterolemia or diabetes |
| 05/05/2005 | US20050096284 RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
| 05/05/2005 | US20050096282 Ribozymes and eye diseases, viruses and kits, macular degeneration or retinitis |
| 05/05/2005 | US20050096277 Methods of prevention and treatment using apolipoprotein analogues |
| 05/05/2005 | US20050096276 Hibernating myocardium can't contract like healthy muscles detection of norepinephrine can predict health of heart muscles |
| 05/05/2005 | US20050096275 Therapy for cell proliferative disorders or skin and other tissue; administering polypeptides |
| 05/05/2005 | US20050096274 Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
| 05/05/2005 | US20050096273 Regulation of matrix metalloproteinases by PSP94 family members |
| 05/05/2005 | US20050096272 Therapeutic method for solid tumors using M161Ag |
| 05/05/2005 | US20050096271 Fusion of polypeptides and immunoglobulin protein; immunotherapy ; antiallergens; antiarthritic agents; anticancer agents; antiinflammatory agents |
| 05/05/2005 | US20050096268 Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| 05/05/2005 | US20050096267 Fusion protein contains amino acid sequence with 9 to 13 residues of arginine; antagonist of Nuclear Factor Activated T cell (NFAT); short effectiveness and no side effects or antigenicity; signal sequence, immunosuppressants, biodrugs |
| 05/05/2005 | US20050096266 Administering trypsin inhibitor and amino acid |
| 05/05/2005 | US20050096264 Methods for treating obesity and related conditions with glycoprotein hormone beta family hormones |
| 05/05/2005 | US20050096263 Novel antiproliferative factor and methods of use |
| 05/05/2005 | US20050096262 Helicobacter pylori adhesion inhibitor |
| 05/05/2005 | US20050096261 Dna-binding polyamide drug conjugates |
| 05/05/2005 | US20050096260 Metal complex-protein composite and oxidation catalyst |
| 05/05/2005 | US20050096259 Neutrophil activation by immune response modifier compounds |
| 05/05/2005 | US20050096258 Methods and compositions for treating gastrointestinal tract mucin production associated disease conditions |
| 05/05/2005 | US20050096257 Administering platelet derived growth factor antagonist and endothelial growth factor antagonist |
| 05/05/2005 | US20050096255 Methods of modulating activity of DXR |
| 05/05/2005 | US20050095710 Antisense modulation of PTP1B expression |
| 05/05/2005 | US20050095704 Using nuclear transplantaion to transfer preferential nuclear material into enucleated animal oocyte; tissue engineering; gene therapy |
| 05/05/2005 | US20050095703 Generating progenitor cells for use in prevention and treatment of cell proliferative, neurodegenerative and pancreatic disorders; regenerative medicine; tissue engineering |
| 05/05/2005 | US20050095684 Protein fusion comprising colony stimulating factor activity for use as tool in rapid stimulation and production of white blood cells and neutrophils |
| 05/05/2005 | US20050095681 Intracellular modulators of apoptopic cell death pathways |
| 05/05/2005 | US20050095676 Novel glycoproteins and methods of use thereof |
| 05/05/2005 | US20050095675 Mucin peptide with immunoenhancing properties |
| 05/05/2005 | US20050095674 Cannabinoid receptor interacting proteins and methods of use |
| 05/05/2005 | US20050095667 Oligomeric lysine-aspartic acid-glutamic acid-leucine amino acid sequence binding protein suppressor; for amplification of immune response to secreted chaperone proteins |
| 05/05/2005 | US20050095655 Solution-based methods for detecting MHC-binding peptides |
| 05/05/2005 | US20050095650 screening for an agent that modulates capsaicin receptor function |
| 05/05/2005 | US20050095612 isolated antibody that specifically binds to polypeptides for diagnosing, preventing and treating autoimmune, cancer and transplant disorders; wound healing agents |
| 05/05/2005 | US20050095604 Novel modulators of amyloid-beta production and uses thereof |
| 05/05/2005 | US20050095587 Molecules for disease detection and treatment |
| 05/05/2005 | US20050095584 Method for determining early HCV seroconversion |
| 05/05/2005 | US20050095581 Viral polypeptide for use as tool in generating immunoreactive particle for diagnosis, prevention and treatment of viral infection |
| 05/05/2005 | US20050095291 Tamper-resistant oral opioid agonist formulations |
| 05/05/2005 | US20050095290 comprising pharmacologically active substance, drug absorbefacient and taurine compound or polyamine; suppressing or preventing damage of the intestinal mucous membrane |
| 05/05/2005 | US20050095270 Introducing large volumes of therapeutics without hearing loss via round window membrane, semicircular canals, cochleostomy and/or stapes footplate |
| 05/05/2005 | US20050095258 Vaccine inhibiting gonadotropin releasing hormone activity in cattle and protecting against bovine herpes virus type 1; polynucleotides, vectors, transformed cells |
| 05/05/2005 | US20050095257 Cancer and viral infections vaccines; increased immunogenicity |
| 05/05/2005 | US20050095253 inducing cancer immune response |
| 05/05/2005 | US20050095249 Protein markers for lung cancer and use thereof |
| 05/05/2005 | US20050095248 Use of inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence |
| 05/05/2005 | US20050095243 Contacting the mixed population of cells with a BLyS(B lymphocte stimulator) antagonist and a CD20 antigen binding antibody; immunoadhesin; B cell neoplasm or a B-cell regulated autoimmune disorder |
| 05/05/2005 | US20050095241 Estrogen receptor modulators and uses thereof |
| 05/05/2005 | US20050095237 Antibodies that kill P2Y10-expressing cells linked to diseases such as inflammatory disorders, autoimmune diseases, allergic reaction, organ and tissue rejection, and mast cell diseases; immunotherapy; use of vaccines; diagnosis |
| 05/05/2005 | US20050095234 Method of inducing or enhancing chondrogenesis with extracellular matrix containing GDF-5 |
| 05/05/2005 | US20050095233 Nutraceutical; hydroxycitric acid, carnitine, biotin, gluconeogenic substrates (e.g. aspartate, lactate, glycerol, amino acid), an eicosapentanoic acid, and one or more of medium chain triglycerides, sesame seeds, sesamin, caffeine, forskolin, 7-keto dehydroepiandrosterone, green tea extract, capsicum |
| 05/05/2005 | US20050095224 Compositions and method for treating hepatitis virus infection |
| 05/05/2005 | US20050095223 Methods of treating autoimmune diseases using IL-21 |
| 05/05/2005 | US20050095216 Administering polypeptide drug that can be pegylated or conjugated to an oligomer; prodrugs, (conjugated)calcitonin or insulin; diabetes or osteoporosis treatment |
| 05/05/2005 | US20050095201 Protein or peptide containing asparagyl-4-aminobutane and/or glutamyl-4-aminobutane residues; diagnostic magnetic resonance imaging |